Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 8/20 | 0.50 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.39 |
| ▸ | CCR2 | P41597 | 1/20 | 0.39 |
| ▸ | PIK3C2B | O00750 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6487974 | 0.90 | MAPT (0.42) | PPARAMAPTMEN1KMT2ANPSR1 | |
| SCHEMBL6501562 | 0.84 | NR4A2 (0.57) | MRGPRX4PPARG | |
| SCHEMBL6491218 | 0.83 | CD38 (0.44) | NPSR1PPARGDCTPP1ALDH1A1L3MBTL1 | |
| SCHEMBL6488659 | 0.82 | PPARA (0.43) | PPARAMRGPRX4NPSR1PPARGDCTPP1 | |
| SCHEMBL6490645 | 0.82 | PTGDR (0.44) | MRGPRX4NPSR1PPARGDCTPP1L3MBTL1 | |
| SCHEMBL6172911 | 0.81 | PPARG (0.48) | MRGPRX4NPSR1PPARGDCTPP1ALDH1A1 | |
| SCHEMBL6489657 | 0.79 | KDM4C (0.42) | MRGPRX4PPARGDCTPP1 | |
| SCHEMBL6489915 | 0.78 | NR4A2 (0.46) | MRGPRX4MAPTPPARGDCTPP1 | |
| SCHEMBL6500955 | 0.78 | KDM4C (0.40) | MRGPRX4PPARGDCTPP1PIK3C2B | |
| SCHEMBL7200058 | 0.78 | FABP3 (0.48) | MRGPRX4PIK3C2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | PPARA 665/4885MRGPRX4 2443/4885MAPT 3168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.